Access cutting-edge endometrial adenocarcinoma treatment through this phase 3 clinical trial at a research site in Cary. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Cary location
Preparing your pre-screening questions…
Access endometrial adenocarcinoma specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related endometrial adenocarcinoma treatment provided free
Check if you qualify for this endometrial adenocarcinoma clinical trial in Cary, NC
No-Cost Study Care
Local to Cary
Convenient for NC residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This is a pragmatic, non-inferiority randomized hybrid decentralized clinical trial. The goal of this study is to determine if one year of maintenance immunotherapy (anti-PD1 agent therapy; pembrolizumab or dostarlimab) is non-inferior to two years of maintenance therapy for patients with advanced/metastatic or recurrent endometrial cancer who have completed the standard course of cytotoxic chemotherapy plus anti-PD1 therapy (chemoimmunotherapy). Our hypothesis is that one year of maintenance therapy will be comparable, or statistically non-inferior, to two years of therapy. This question has clinical importance as there is not a clear optimal duration for maintenance immunotherapy in this setting, and checkpoint inhibitors are associated with their own unique toxicity profile (immune-related adverse events) and incremental costs to patients and the healthcare system at large. Patients who respond favorably to primary therapy and choose to enroll will be randomized (1:1) after completion of chemoimmunotherapy to one-year of maintenance anti-PD1 therapy (1-year arm) or to two-years of maintenance anti-PD1 therapy (2-year arm). The primary endpoint is progression-free survival (PFS) determined over the course of at least 3 years from randomization of patient follow up. Secondary endpoints are overall survival (OS) and incidence of immune-related adverse events (irAE). Finally, exploratory objectives include measuring differences in gut and vaginal microbial profiles and innate immune system (IIS) tumor profiles and correlation with clinical outcomes (PFS, OS).
Sponsor: UNC Lineberger Comprehensive Cancer Center
Yes, this clinical trial (NCT07867002) has an active research site in Cary, NC that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for endometrial adenocarcinoma treatment options in Cary, NC, this clinical trial (NCT07867002) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Cary research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced endometrial adenocarcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all endometrial adenocarcinoma clinical trials near you to find additional studies recruiting in your area.
See all alzheimers disease clinical trials recruiting in Cary — not just this study.
Browse Alzheimers Disease Trials in Cary →